How mRNA vaccines build lasting protection against infections
Mechanisms of protective memory CD8 T-cell induction by mRNA-LNP vaccines
This project looks at how mRNA vaccines help your body create special immune cells that remember and fight off future infections, like those in your airways.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11088756 on NIH RePORTER |
What this research studies
Our bodies have special immune cells called CD8 T-cells that find and destroy virus-infected cells. After an infection, some of these cells become 'memory' cells, ready to quickly fight off the same virus if it returns. This project explores how modern mRNA vaccines, like those used for COVID-19, train these memory CD8 T-cells to provide strong, long-lasting protection. While much is known about how these vaccines create antibodies, we want to understand how they also create these powerful T-cells, which could be crucial for fighting many types of viral infections, including those in the airways.
Who could benefit from this research
Good fit: This foundational research does not directly involve patient participation at this stage, but future applications could benefit individuals susceptible to severe viral infections.
Not a fit: Patients currently seeking immediate treatment for an active infection would not directly benefit from this early-stage mechanistic work.
Why it matters
Potential benefit: If successful, this work could lead to improved mRNA vaccines that offer stronger and longer-lasting protection against a wider range of viral infections, including those affecting the lungs.
How similar studies have performed: mRNA-LNP vaccines have already shown great success in inducing antibody responses against viruses like SARS-CoV-2, and preliminary work in animal models suggests they can also induce protective T-cell responses.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Sigal, Luis J — Thomas Jefferson University
- Study coordinator: Sigal, Luis J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.